Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib plus BR or R-CHOP versus placebo plus BR or R-CHOP in previously treated indolent non-Hodgkin lymphoma
2013-003093-27Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ibrutinib in indolent lymphoma, follicular lymphoma (FL) and marginal zone B-cell lymphoma (MZL) (4 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Progression-free survival. Started Nov 2013; status: completed.
02
Drugs
ibrutinib
03
Conditions
indolent lymphomafollicular lymphoma (FL)marginal zone B-cell lymphoma (MZL)
Beyond the preview
Go deeper on 2013-003093-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003093-27.